Shanghai Henlius Biotech (FRA:2E8) Other Current Receivables: €2.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E8 Shanghai Henlius Biotech Inc FRA:2E8
50 GF Score
Price €7.30
GF Value €3.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Henlius Biotech Other Current Receivables?

Shanghai Henlius Biotech FRA:2E8 -2.67% 50 Other Current Receivables is €2.1 Mil as of Dec. 2025. GuruFocus rates FRA:2E8 with a GF Score™ of 50/100 and a GF Value™ of €3.38 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shanghai Henlius Biotech's Other Current Receivables for the quarter that ended in Dec. 2025 was €2.1 Mil.

Shanghai Henlius Biotech's quarterly Other Current Receivables declined from Dec. 2024 (€5.76 Mil) to Jun. 2025 (€0.75 Mil) but then increased from Jun. 2025 (€0.75 Mil) to Dec. 2025 (€2.11 Mil).

Shanghai Henlius Biotech's annual Other Current Receivables declined from Dec. 2023 (€10.59 Mil) to Dec. 2024 (€5.76 Mil) and declined from Dec. 2024 (€5.76 Mil) to Dec. 2025 (€2.11 Mil).

Shanghai Henlius Biotech Other Current Receivables Related Terms

Shanghai Henlius Biotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Shanghai Henlius Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Henlius Biotech Other Current Receivables Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 0.00 40.38 10.59 5.76 2.11

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.59 5.73 5.76 0.75 2.11
FRA:2E8
50GF Score
Shanghai Henlius Biotech Inc FRA:2E8
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Henlius Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €2.1 Mil mean?
Shanghai Henlius Biotech (FRA:2E8) has a Other Current Receivables of €2.1 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Shanghai Henlius Biotech and its competitors.
Is Shanghai Henlius Biotech's Other Current Receivables too high?
Shanghai Henlius Biotech's current Other Current Receivables is €2.1 Mil. Overall, Shanghai Henlius Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Other Current Receivables compare to VRTX and REGN?
Shanghai Henlius Biotech's Other Current Receivables of €2.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Shanghai Henlius Biotech and its competitors. Shanghai Henlius Biotech's current Other Current Receivables is €2.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (FRA:2E8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €7.30 — trading 116% above its estimated fair value. The current Other Current Receivables is €2.1 Mil. Shanghai Henlius Biotech's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Shanghai Henlius Biotech (FRA:2E8), the current Other Current Receivables is €2.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued. The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38. GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.

Key valuation signals for FRA:2E8:

  • Other Current Receivables: €2.1 Mil
  • GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Henlius Biotech Business Description

Other Exchanges 02696:Hong Kong
Address B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score

Get the complete analysis for FRA:2E8

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.30
Price
€3.38
GF Value